Medical marijuana; requiring final harvest and production batch samples to be tested for certain pesticide analytes; effective date.
HB3013 amends Oklahoma’s Medical Marijuana and Patient Protection Act to require that final harvest batch samples and final production batch samples be tested for a specified list of pesticide analytes. The bill sets allowable thresholds for dozens of pesticides and requires medical marijuana testing laboratories to include these analytes in their contaminant testing before marijuana or marijuana products can be transferred, sold, or further processed, unless otherwise authorized by law. The measure also retains and reinforces the broader framework governing medical marijuana testing laboratories, including accreditation, chain-of-custody, quality assurance, and Authority oversight.
In addition to the pesticide-testing mandate, the bill sits within a detailed regulatory structure for laboratory licensure and compliance. It preserves requirements for testing of microbials, mycotoxins, residual solvents, heavy metals, THC potency, and terpenoid content, while also tying compliance to batch separation, record retention, inspections, and reporting. The bill’s effective date is November 1, 2026.
HB3013 would directly amend 63 O.S. Section 427.17, expanding the statutory testing requirements for medical marijuana by adding mandatory pesticide analyte screening for final harvest and production batches. It would affect licensed medical marijuana testing laboratories, growers, processors, dispensaries, and the Oklahoma Medical Marijuana Authority by making pesticide compliance a required part of the testing and release process for medical marijuana products. The bill would also reinforce enforcement authority through existing inspection, accreditation, and product recall mechanisms.
No committee transcript or vote record was provided, so there is no documented floor or committee debate to gauge sentiment. Based on the bill text, the measure appears to reflect a regulatory and public-safety approach to medical marijuana oversight, with an emphasis on product testing, contamination control, and consumer protection. The absence of recorded opposition or support in the provided materials means the overall sentiment cannot be determined from votes or discussion history.
The most likely points of contention are the added compliance burden on testing laboratories and medical marijuana businesses, especially the cost and operational impact of expanded pesticide testing and the need to meet specific threshold standards. Laboratories and industry participants may also be concerned about the detailed list of analytes, the possibility of product failures or recalls, and how the new requirements interact with existing batch-sizing, validation, and accreditation rules. On the other hand, supporters would likely emphasize patient safety, product purity, and stronger oversight of contaminated cannabis products.